PHAR — Pharming Group N.V.

Summary of Pharming Group N.V. Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenues: $97.3 million, up 30% year-over-year.
• Operating Profit: $15.8 million, nearly 4x the previous year's $4.1 million.
• Gross Profit: $90.2 million, a 33% increase, resulting in a gross margin of 93%.
• Operating Cash Flow: $32 million, restoring cash position to pre-Abliva acquisition levels of approximately $169 million.
• Year-to-Date Performance: Total revenues for the first nine months reached $269.6 million, a 32% increase.

2. Strategic Updates and Business Highlights:

• Product Performance:
  • RUCONEST: Revenue of $82 million, a 29% increase, driven by new prescribers and patient enrollments.
  • Joenja: Revenue of $15.1 million, up 35%, with a 25% increase in patients on treatment.
• Growth Initiatives: Anticipated expansion in pediatric indications for Joenja, with FDA priority review and a PDUFA date set for January 31, 2026.
• Pipeline Development: Progress in clinical trials for KL1333 in primary mitochondrial disease and ongoing studies for APDS, with potential for significant market expansion based on new research findings.
• Cost Management: A reduction in G&A headcount to optimize capital deployment towards high-growth initiatives.

3. Forward Guidance and Outlook:

• Revenue Guidance: Raised to $365 million - $375 million for 2025, up from previous guidance of $335 million - $350 million, reflecting strong product performance.
• Operating Expenses: Expected to be between $304 million - $308 million, including nonrecurring costs related to the Abliva acquisition.
• Long-term Vision: Focus on building a leading global rare disease company with a robust pipeline and sustainable growth.

4. Bad News, Challenges, or Points of Concern:

• Market Competition: Concerns about the impact of new oral therapies (e.g., sebetralstat) on RUCONEST's market share, although management believes RUCONEST serves a different patient demographic.
• Withdrawal from European Markets: Plans to cease RUCONEST commercialization in certain European countries due to financial sustainability concerns, which may limit access for some patients.
• Regulatory Risks: Uncertainty regarding the timeline and success of the VUS reclassification process, which could affect patient identification and market potential for Joenja.

5. Notable Q&A Insights:

• RUCONEST Competition: Management emphasized the unique value proposition of RUCONEST for severe HAE patients, suggesting limited direct competition with oral therapies.
• Joenja Pediatric Launch: Anticipated quick conversion of identified pediatric patients currently in early access programs once the product is formally approved.
• Patient Identification: Ongoing efforts to identify APDS patients, with potential for a significant increase in the patient population based on recent research findings suggesting higher prevalence rates.
• Capital Allocation: Emphasis on disciplined capital allocation with no immediate plans for large M&A transactions, focusing instead on organic growth and existing pipeline opportunities.

This summary encapsulates the key points from Pharming's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and potential challenges faced by the company.